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http://www.cancerci.com/content/12/1/21PRIMARY RESEARCH Open AccessThe stem cell factor antibody enhances the
chemotherapeutic effect of adriamycin on
chemoresistant breast cancer cells
Neil D Jelly1*, Issam I Hussain1, Jennifer Eremin2, Oleg Eremin2,3 and Mohamed El-Sheemy1,2Abstract
Background: The outcome of chemotherapy in breast cancer is strongly influenced by multidrug resistance (MDR).
Several surrogate markers of chemoresistance have been identified including - CD24 (cluster differentiation 24)
expression, stem cell growth factor (SCF), B-cell lymphocyte protein 2 (Bcl-2) and annexin V. The present study
aimed to examine the expression of CD24 in the sensitive breast cancer cell line MCF-7 (Michigan Foudation-7) and
MCF-7/adriamycin resistant (MCF-7/AdrRes) cells, and, if minimal effective doses of the anthracycline drug
adriamycin (0.579 μM and 88.2 μM) would be enhanced by the antibody to SCF (anti-SCF).
Methods: CD24 expression was analysed by flow cytometry. Both Bcl-2 and annexin V protein expression were
quantitatively assessed by the enzyme-linked immunosorbent assay (ELISA).
Results: In MCF-7/AdrRes cells the expression of CD24 was significantly higher compared to MCF-7 cells, 86.6% and
16.3% (p< 0.001), respectively. Bcl-2 expression was significantly increased in the presence of adriamycin and SCF
(p< 0.038) and decreased in the presence of adriamycin and anti-SCF. When adriamycin, anti-SCF and SCF were
combined or when adriamycin was used alone the decrease in Bcl-2 expression was insignificantly altered. In the
presence of both adriamycin and SCF the expression of annexin V was decreased. However, it was significantly
increased in the presence of adriamycin and anti-SCF (p< 0.042), as well as adriamycin, anti-SCF and SCF
combined.
In MCF-7 cells the effect of adriamycin alone or with either SCF, anti-SCF or anti-SCF or SCF combined, did not
significantly alter the expression of Bcl-2. However, in the presence of both adriamycin and SCF the expression of
annexin V was decreased, but was significantly increased in the presence of adriamycin and anti-SCF (p< 0.001),
adriamycin, anti-SCF and SCF combined and adriamycin alone. Our results demonstrate that anti-SCF with low dose
of adriamycin reduces Bcl-2 expression in MCF-7/AdrRes cells and increases annexin V expression in both MCF7/
AdrRes and MCF-7 cells.
Conclusion: Adding anti-SCF to the chemotherapeutic regime of adriamycin may strongly enhance its
chemotherapeutic effect in the treatment of patients with breast cancer.Introduction
Breast cancer is the most common form of cancer and
the principal cause of death from cancer among women
worldwide [1] Neoadjuvant chemotherapy (NAC) is fre-
quently used to treat breast cancer patients particularly
those with locally advanced disease in order to downstage
and downgrade the disease [2] However, a complete
pathological response is only observed in 30% of patients,* Correspondence: njelly@lincoln.ac.uk
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reproduction in any medium, provided the orwhilst 70% of patients show an incomplete or no patho-
logical response [3-7] Despite advances in understanding
the molecular basis of breast cancer the poor responses to
chemotherapeutic agents are not well defined. Several fac-
tors are attributed to drug resistance including - drug
efflux, cancer stem cells (CSCs), cytokine overexpression
and resistance to drug-induced apoptosis [8,9]. The ability
to predict the response to NAC may result in a more
cost-effective therapy. Therefore, targeting therapy to these
potential responders would also avoid significant and
unnecessary morbidity in nonresponders [3]. Adriamycin. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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ever; breast cancer cells often become resistant to
its effects. Critical apoptotic pathways, which are initiated
by adriamycin and other cytotoxic drugs, are altered by
several mechanisms resulting in chemoresistance. The
ability to evade programmed cell death is a phenotypic
characteristic of most tumours [10]. Negative regulators
of apoptosis are amongst the most frequently studied
particularly the proto-oncogene Bcl-2. Both B-cell lym-
phocytes and CSCs are characterised by extracellular
protein expression of CD24, which may have an import-
ant role in both tumour growth and resistance. None-
theless, it is thought that cancer stem cells (CSCs) are
involved in carcinogenesis, local invasion and metastasis
which play a key role to both radiotherapy and chemo-
therapy resistance [9]. Also, SCF may be co-expressed
with Bcl-2 however their relationship requires further
definition. Recently, an antibody to SCF (anti-SCF) signifi-
cantly enhanced the cytotoxic effects of chemotherapy
in human resistant haematological cancer [11]. However,
it is not known whether anti-SCF enhances cytotoxicity
in solid cancer e.g. breast cancer. On developing new
molecular therapeutics understanding pharmacodynamic
endpoints is critical. One of the characteristics of apop-
tosis is the externalization of phosphatidylserine (PS). It is
documented that Annexin V is able to bind with high
specificity to PS [12]. Therefore, the aim of this study was
to evaluate the expression of CD24, and the ability of
anti-SCF to enhance adriamycin by examining their com-
bined effects on both Bcl-2 and annexin V expression in
MCF-7 and MCF-7/AdrRes breast cancer cells.
Materials and methods
Cell culture of MCF-7 and MCF-7/AdrRes cell lines
The MCF-7 and MCF-7/AdrRes human breast adenocar-
cinoma cell lines were a kind gift from Queens Medical
Centre, University of Nottingham, UK [3,9]. The MTT 3(4,
5 Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
assay was used to establish minimal effective dose concen-
trations of adriamycin. In MCF-7/AdrRes cells the IC50
concentration for adriamycin was 88.2 μM versus 0.579 μM
in MCF-7 cells. The cells were grown in tissue culture
medium (TCM) consisting of RPMI-1640 (with L-glutam-
ine) (Sigma Aldrich, UK), supplemented with 10% foetal
calf serum (FCS) (Sigma Aldrich, UK), and 100 units/ml of
penicillin/and 0.1- mg/ml of streptomycin (Sigma Aldrich,
UK), and placed in an incubator. The incubator was set at
0.05 CO2 and humidified at 37°(C) throughout the study.
All cells used subsequently in this study were between 15–
20 passages. 2.2 Immunophenotyping for CD24 Expression
Using Flow Cytometry Cultured cells were resuspended
(0.5× 106 cells) in ice cold Phosphate Buffered Saline (PBS)
and 10% FCS. Cells (0.5× 106) were then incubated for 30
minutes (mins) at 4°C with primary CD24 fluoresceinisothiocyanate (FITC) murine monoclonal antibody (MoA)
(Cambridge Biosciences, Cambridge, UK), which was pre-
pared by diluting in 3% bovine serum albumin (BSA)
and PBS (BSA/PBS) to a final concentration of 1 in 20.
Cells were washed in PBS centrifuged at 300 g for 5 mins
and resuspended in 500μls of ice cold PBS with 10% FCS
for analysis by the Epics xL flow cytometer (Beckman
Coulter, High Wycombe, UK) which was equipped with
a standard argon laser for 488 nm excitation and with
525 nm band pass (FL1), 575 nm band pass (FL2),
620 nm band pass (FL3) and 675 nm band pass (FL4)
filters.
Treatment of MCF-7 and MCF-7/AdrRes cells
MCF-7 and MCF-7/AdrRes cell lines were cultured
(5 × 103 cells perwell) and were treated with adriamycin
(Sigma Aldrich, UK) using 0.579 μM and 88.2 μM, re-
spectively, to be effective in accordance with IC50 con-
centrations, 0.4 μg/ml anti-SCF (PeproTech EC LTD,
UK), and/or 100 units/ml of SCF (0.4 μg/ml of anti-SCF
fully inhibits the biological activity of SCF as previously
established by our colleagues) [11]. The final concentra-
tion of 100 μl/well of treatment was incubated with the
cells using the following parameters: (1) adriamycin with
SCF; (2) adriamycin with anti-SCF; (3) adriamycin with
both SCF and anti-SCF; (4) adriamycin alone. Cells were
treated without adriamycin using the same parameters.
Five replicates of each treated culture (2.5 × 104 cells)
were set and incubated for 48hs.
Analysis of bcl-2 using the quantitative ELISA assay
The human Bcl-2 ELISA kit (Bender Med SystemsTM)
was used to quantitatively analyse Bcl-2 protein, as
described previously [11]. Cells were washed twice with
PBS and centrifuged at 500 g for 5 mins. The cell pellets
were resuspended at 5 × 106/ml of lysis buffer for 60 mins
at room temperature (RT). Cells were re-centrifuged and
resuspended in sample diluent (serum matrix, buffered
solution) 1:5. Each sample of cell lysate and lyophilized
standards of serially diluted Bcl-2 (100μls) were dupli-
cated and added with FITC-labelled biotin-conjugate
(anti-Bcl-2 murine MoA) diluted 1:100 in the assay
buffer (PBS, with 1% Tween 20 and 10% BSA), and incu-
bated in a 96-microwell plate coated with murine MoA
of human Bcl-2 for 2hs at RT. Using wash buffer (PBS
containing 1% Tween 20) the microwell strips were
thoroughly washed. Streptavidin-horseradish peroxidase
(HRP) - conjugate was then added to all wells at a dilu-
tion of 1:100 in the assay buffer and incubated for 1 h at
RT. Microwell strips were thoroughly washed again and
then TMB substrate solution (1 × tetramethylbenzidine
added to 1 × 0.02% - buffered hydrogen peroxide) was
added for 10 mins and incubated at RT. The change in
colour from the substrate reaction was monitored and
Figure 1 Expression of CD24 in MCF-7/AdrRes cells. Cells (104)
were analysed by flow cytometry using CD24 monoclonal
antibody (FITC). The histogram shows high level expression for
CD24 in cells (positives - 87%). Both the plots of forward scatter
(FSC) versus side scatter (SSC) were used to gate cells (not shown).
To show positivity of CD24 an (FL1) plot was used (shown). For the
Epics xL flow cytometer λ excitation= 488 nm and λ
emission= 525 nm.
Figure 2 Expression of CD24 in MCF-7 cells. Cells (104) were
analysed by flow cytometry using CD24 monoclonal antibody (FITC).
The histogram shows low level expression for CD24 in cells
(positives - 16%). Both the plots of forward scatter (FSC) versus side
scatter (SSC) were used to gate cells (not shown). To show positivity
of CD24 an (FL1) plot was used (shown). For the Epics xL flow
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acid). The absorbance of each microwell was then read
at 450 nm using an ELISA plate reader (BMG Lab Tech-
nologies, Germany).
Analysis of annexin V using the quantitative ELISA assay
The human annexin V ELISA kit (Bender Med Sys-
temsTM) was used to quantitatively analyse annexin V
protein, as previously reported [11]. Cells were washed
twice with PBS and centrifuged at 500 g for 5 mins. The
cell pellets were re suspended in sample diluent (serum
matrix, buffered solution) (1:2). Each sample and lyophi-
lized standards of serially diluted annexin V (100μls)
were duplicated and added with FITC-labelled biotin-
conjugate (anti-annexin V murine MoA) diluted 1:100 in
the assay buffer (PBS, with 1% Tween 20 and 10% BSA).
Samples were then incubated in a 96-microwell plate
coated with murine MoA of human annexin V for 2hs at
RT. Using wash buffer, (PBS containing 1% Tween 20)
the microwell strips were washed thoroughly. Then at a
dilution of 1:200 in the assay buffer, streptavidin-horse-
radish peroxidase (HRP) - conjugate was added to all
wells and incubated for 1 h at RT. Microwell strips were
again washed thoroughly with wash buffer with TMB
substrate solution (1 × tetramethylbenzidine added to
1 × 0.02% - buffered hydrogen peroxide) then being
added for 10 mins at RT. The change in colour from the
substrate reaction was monitored and was terminated by
adding stop solution (1 M phosphoric acid). The absorb-
ance of each microwell was read at 450 nm using the
ELISA plate reader (BMG Lab Technologies, Germany).
Statistical analysis
The mean± standard error of all readings underwent stat-
istical analysis, whenever appropriate. Independent two-
sample, two-tailed tests were used to analyse the differ-
ence in mean values of CD24 expression. Multi-factorial
(three way) Analysis of Variance (ANOVA) was used to
analyse the two response variables of Bcl-2 and annexin V.
Statistical significance is recorded when the p-value was
less than 0.05 (P< 0.05).
Results
CD24 expression
CD24 expression was measured by flow cytometry in
MCF-7/AdrRes and MCF-7 cell lines (Figures 1 and 2).
Levels of CD24 expression ranged from 86.6 ± 3.0% in
resistant cells, compared with 16.3 ± 1.9% in wild type
cells which was highly significant (p< 0.001).
Effect of adriamycin/anti-SCF on bcl-2 expression
in MCF-7/AdrRes and MCF-7 cells
The therapeutic effects of adriamycin, anti-SCF and SCF
on Bcl-2 expression were examined by ELISA in MCF-7and MCF-7/AdrRes cells, after being treated simultan-
eously for 48 hrs. The combination of adriamycin and
SCF significantly increased Bcl-2 expression in MCF-7/
AdrRes cells (p< 0.038), with a decrease in Bcl-2 expres-
sion observed after treatment with adriamycin and anti-
SCF, adriamycin and both SCF and anti-SCF combined
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Figure 3 Effect of Adriamycin/Anti-SCF on Bcl-2 Expression in MCF-7/AdrRes Cells. Cell lysates were used to determine the expression of
Bcl-2 using ELISA after treatment with the drug adriamycin (D) + SCF, D + anti-SCF, D + SCF+ anti-SCF and Drug alone. For each individual
experiment data are represented as the mean± SE of duplicate determinations of 1.25 × 104 cells. ANOVA showed a significant* difference
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http://www.cancerci.com/content/12/1/21was no significant difference in Bcl-2 expression observed
after treatment with either adriamycin and SCF or adria-
mycin and anti-SCF, unlike in MCF-7/AdrRes cells.
Similarly, no significant difference in Bcl-2 expression
was observed in cells after treatment with adriamycin
and both anti-SCF and SCF combined, or adriamycin
(Figure 4).
Effect of adriamycin/anti-SCF on annexin V expression
in MCF-7/AdrRes and MCF-7 cells
To determine the therapeutic effects of adriamycin, anti-
SCF and SCF on annexin V expression, MCF-7 and
MCF-7/AdrRes cells were also treated simultaneously
for 48 hrs before being examined by ELISA. The expres-
sion of annexin V was decreased in MCF-7/AdrRes cells
after treatment with adriamycin and SCF, but signifi-
cantly increased after treatment with adriamycin and
anti-SCF (p< 0.042), adriamycin and both SCF and anti-



























Figure 4 Effect of Adriamycin/Anti-SCF on Bcl-2 Expression in MCF-7
using ELISA after treatment with the drug adriamycin (D) + SCF, D + anti-SC
data are represented as the mean± SE of duplicate determinations of 1.25
between treatments (D) ± SCF, D ± anti-SCF, D ± SCF ± anti-SCF and Drug alwas also a decrease in annexin V expression in MCF-7
cells after treatment with adriamycin and SCF, with a
significant increase observed after treatment with adria-
mycin and anti-SCF (p< 0.001), adriamycin and both
anti-SCF and SCF combined and adriamycin alone
(Figure 6).
Discussion
Neoadjuvant chemotherapy is used as a multimodality
treatment for breast cancer patients with large and lo-
cally advanced disease. One important component of the
drug combinations used are anthracyclines (adriamycin),
which are given in association with other chemothera-
peutic agents such as Taxanes [13]. However, this treat-
ment is compromised by the presence of multidrug
resistance (MDR) resulting in treatment failure and
subsequent increased morbidity and mortality. Several
covariate mechanisms are responsible for multi-drug
resistance in breast cancer cells including increased drugD+SCF+anti-SCF Drugs (D)
 Treatment
Cells. Cells lysates were used to determine the expression of Bcl-2
F, D + SCF+ anti-SCF and Drug alone. For each individual experiment






























Figure 5 Effect of Adriamycin/Anti-SCF on Annexin V Expression in MCF7/AdrRes Cells. Cells were used to determine the expression of
annexin V using ELISA after treatment with the drug adriamycin (D) + SCF, D + anti-SCF, D + SCF+ anti-SCF and Drug alone. For each individual
experiment data are represented as the mean± SE of duplicate determinations of 1.25 × 104 cells. ANOVA showed a significant* difference





























Jelly et al. Cancer Cell International 2012, 12:21 Page 5 of 8
http://www.cancerci.com/content/12/1/21efflux (P-glycoprotein-P-gp), CSCs (CD24), drug detoxi-
fication (glutathione S-transferase) deregulated apoptosis
(Bcl-2 overexpression) and overexpression of cytokines
(SCF) [8]. The anti-apoptotic expression of Bcl-2 is well
documented and its affects on tumourigenic activity
[14]. CD24 is a phenotypic surface marker for granulo-
cytes, Bcl’s and CSCs, which are implicated in resistance
to both chemotherapy and radiotherapy. Subsequently,
some of these progenitor cells differentiate into new
mature tumour cells with a chemoresistant phenotype
[15]. CSCs were originally described in haematologic
malignancies, but this emerging concept is now also
applied to solid tumours.
Consequently, there is an increasing need to develop
assays which determine the pharmacodynamic effects of
both existing and new cancer therapeutics [10]. Annexin
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Figure 6 Effect of Adriamycin/Anti-SCF on Annexin V Expression in M
using ELISA after treatment with the drug adriamycin (D) + SCF, D + anti-SC
data are represented as the mean± SE of duplicate determinations of 1.25
treatments D± anti-SCF, D ± SCF± antiSCF and Drug alone and (D) ± SCF.which binds with high affinity (K = 10-9 M) to phospha-
tidylserine (PS) residues that are displayed on the outer
surface of apoptotic cells [16]. This is not only an
alternative non-invasive technique in order to quantify
apoptosis and determine pharmacodynamic endpoints
after treatment with anti-cancer therapies, but may
also be of potential benefit when developing new mole-
cular therapies.
The administration of high-dose chemotherapy facili-
tated by autologous progenitor cell support such as SCF,
the haematopoietic growth factor, is being more frequently
applied to the treatment of cancer [17]. In patients with
breast and ovarian cancer, lymphoma and multiple mye-
loma and in conjunction with G-CSF (Granulocyte Colony
Stimulating Factor) SCF is used in clinical practice to
mobilise CD34+ cells into peripheral blood [18]. In the
past SCF expression has been demonstrated in malignantD+SCF+anti-SCF Drugs (D)
Treatment
CF-7 Cells. Cells were used to determine the expression of annexin V
F, D + SCF+ anti-SCF and Drug alone. For each individual experiment
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http://www.cancerci.com/content/12/1/21melanomas, pancreatic cancer, glioma cells, gastrointes-
tinal stromal tumours (GIST) and colon cancer [19-23].
Therefore, in preventing chemotherapy induced haemato-
logical depression in cancer patients the clinical relevance
of SCF and other growth factors or cytokines which may
possibly influence tumour proliferation and survival at the
level of cancer stem cells, opens questions. Another major
concern about this treatment is that SCF may induce pro-
tection against chemotherapy in tumour cells that also
express the SCF receptor (c-Kit), which has been observed
in both haematological and solid cancers. It has been
suggested that the maintenance and normal growth of
mammary epithelial tissue is influenced by the ckit/SCF
pathway with their progressive loss occuring adjacent to
malignant transformation [24]. However, one alternative
suggestion is that SCF modulates tumour growth and
angiogenesis via the involvement of mast cells [25]. Con-
sequently, further examination of the effects of SCF on
breast cancer growth and progression is required. Add-
itionally, the activity of anti-SCF may have a multiple role
in antagonising the negative growth of breast cancer cells
by affecting those pathways involved in CSC and Bcl-2
mediated chemoresistance.
The difference in CD24 expression in MCF-7/AdrRes
and MCF-7 cells was demonstrated in this study, and
also the ability of anti-SCF to enhance the effects of
adriamycin chemotherapy. To the best of our knowledge
it is the only study to analyse the synergistic effects of
adriamycin and anti-SCF in MCF-7/AdrRes and MCF-7
cells, and their combined effects on Bcl-2-related resist-
ance and annexin V-related cytotoxicity.
Initially, the IC50 minimal dose concentrations obtained
from in vitro cytotoxicity assays showed a 1.52×102 fold
higher resistance to adriamycin in MCF-7/AdrRes cells,
compared with MCF-7/WT cells (88.2 μM and 0.579 μM),
respectively. In MCF-7/AdrRes cells there was a significant
increase in the positivity of CD24 expression compared
with a markedly low level in MCF-7 cells. Recently, there
have been high levels of CD24 observed in mouse xeno-
grafts derived from both CD44+/CD24-/low and CD44
+/CD24hi breast cancer cells suggesting important role for
CD24 in tumour growth, whilst CD44+/CD24-/low breast
cancer cells were not associated with increased tumouri-
genicity [26]. Further to this, ovarian tumour specimens of
a patient showed a sub-population enriched for ovarian
CSCs defined by CD24 phenotype. It was observed that
the CD24+ sub-population remained quiescent and more
chemoresistant compared with the CD24-/low fraction as
well as having stem cell-like characteristics such as specific
capacity for self-renewal and differentiation. Additionally,
CD24+ cells were able to form tumour xenografts in nude
mice, whereas equal numbers of CD24- cells did not [27].
Finally, CD24+ cells had lower E-cadherin mRNA levels in
comparison to CD24- cells, whilst the mRNA levels ofcertain stemness genes (Nestin, β-catenin, Bmi-I, Oct4,
Oct3/4, Notch1 and Notch4) were more highly expressed.
Interestingly, both adriamycin and SCF combined sig-
nificantly increased Bcl-2 expression in MCF-7/AdrRes
cells, however in MCF-7/WT cells there was no effect.
In addition to its cell cycle inhibitory function which
markedly increases the cell cycle withdrawal into the G0
quiescent phase Bcl-2 also has the ability to enhance cell
survival [28]. This also protects cells from the effects of
chemotherapy with increased expression of CD24 being
a further contributory factor, modulating not only Bcl-2
expression, but also the presence of CSC populations.
The decrease in Bcl-2 expression observed after treatment
with both adriamycin and anti-SCF has reduced Bcl-2
related resistance. Subsequently, there were higher annexin
V levels observed in MCF-7/AdrRes (and MCF-7/WT
cells) after treatment with adriamycin and anti-SCF indi-
cating increased apoptosis, but these were decreased after
treatment with adriamycin and SCF. This result differs
with our previous study in MCF-7/paclitaxel resistant cells
(unpublished data, Jelly et al., 2008). The mechanistic
action of each drug combined with anti-SCF may sub-
sequently not only affect Bcl-2 expression, but also the
pathways involved in apoptosis leading to annexin V
expression, therefore explaining these differences.
Other studies have also reported that Bcl-2 may have
distinct biological properties depending on the antican-
cer agent used when affecting antineoplastic sensitivity
[29]. The major advantage of using anti-SCF is that it
specifically inhibits SCF and not other key cytokines un-
like other generic tyrosine kinase inhibitors such as ima-
tinib, which block several cytokine receptors including
c-Kit [30]. In addition there is also the potential when
administering this as a combined therapy with adria-
mycin, to slow the proliferation of normal CD34+
bone marrow cells protecting them from chemotherapy-
induced myelosuppression. Also, it may be possible to
shorten post-chemotherapy neutropenia. However, nor-
mal CD34+ bone marrow cells may become susceptible
to cytotoxicity when treating with chemotherapy if anti-
SCF reduces Bcl-2 expression [11]. If this combined
therapy increases apoptosis in these normal cells of the
bone marrow then any therapeutic advantage gained
may be lost and therefore further evaluative studies are
warranted. In this study it has been demonstrated that
Bcl-2 expression is reduced in MCF-7/AdrRes cells after
treatment with adriamycin and anti-SCF with annexin V
being increased in both MCF-7/AdrRes and MCF-7/WT
cells. This possible advantage as well as their cytotoxic
effects on normal CD34+bone marrow cells requires fur-
ther investigative study. Both adriamycin and anti-SCF
combined may potentially improve response to treatment
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